GlassScriptPhysician profile
Michael I Rickoff
NPI 1851373724
$15,503.05
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $676 · 2020: $3,648 · 2021: $5,471 · 2022: $4,782 · 2023: $912 · 2024: $14.19.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $910 · Education: $16.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $909.66 |
| Education | $16.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $8,752.10 | 2021-2022 | |
| Qol Medical, LLC | $3,627.68 | 2019-2023 | Sucraid |
| Abbvie INC. | $1,134.67 | 2019-2023 | |
| Celgene Corporation | $655.10 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $268.67 | 2019-2023 | Xifaxan, Plenvu |
| Merck Sharp & Dohme LLC | $243.63 | 2019-2023 | Dificid |
| Pfizer INC. | $120.97 | 2022-2023 | |
| Janssen Biotech, INC. | $103.99 | 2019-2023 | Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $100.93 | 2019-2023 | Entyvio |
| Ironwood Pharmaceuticals, INC | $73.00 | 2022-2023 | Linzess |
| Ferring Pharmaceuticals INC. | $66.53 | 2022-2023 | Rebyota |
| Gilead Sciences, INC. | $53.75 | 2022-2023 | |
| Intercept Pharmaceuticals, INC. | $47.01 | 2019-2023 | Ocaliva |
| Nestle Healthcare Nutrition INC. | $45.60 | 2021-2023 | |
| Alnylam Pharmaceuticals INC. | $42.02 | 2022-2023 | Givlaari |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $32.50 | 2022-2024 | |
| Daiichi Sankyo INC. | $28.63 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $17.50 | 2022 | |
| Redhill Biopharma INC. | $17.19 | 2021 | |
| Ardelyx, INC. | $16.45 | 2022 | |
| Medtronic, INC. | $16.07 | 2023 | Bravo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.15 | 2023 | |
| Shire North American Group INC | $12.91 | 2019 | |
| Ucb, INC. | $12.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Rickoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.